Moreover, pharmacological administration of recombinant FGF21 reduced serum triglyceride (TG) and low-density lipoprotein cholesterol (LDL) while increased high-density lipoprotein cholesterol (HDL) levels, and it reversed steatosis in mouse models of obesity and diabetes (14, 17, 24). This evidence concerns the gene FGF21 and steatosis.